Imatinib, a BCR-ABL tyrosine kinase inhibitor, is known to cause mild to moderate cutaneous reactions in up to approximately 20% of patients. It rarely causes severe reactions, such as Stevens–Johnson syndrome, which can be life threatening. Typically, these rashes occur within two months of initiating therapy. We report a case of Stevens–Johnson syndrome induced by imatinib after several years of therapy, but later successfully was treated with nilotinib therapy.
HsiefHJChanALLinSJ. Stevens–Johnson syndrome induced by combination of imatinib and allopurinol. Chemotherapy2009; 55: 197–199.
2.
MahapatraMMishraPKumarR. Imatinib-induced Stevens–Johnson syndrome: recurrence after re-challenge with a lower dose. Ann Hematol2007; 86: 537–538.
3.
ValeyrieLBastuji-GarinSRevuzJ. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol2003; 48: 201–206.
4.
RoujeauJCSternRS. Severe adverse cutaneous reactions to drugs. N Engl J Med1994; 331: 1272–1285.
5.
WeiGRafiyathSLiuD. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol2010; 3: 47–47.
6.
SeverinoGChillottiCLisaRD. Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors. Ann Pharmacother2005; 39: 162–164.
7.
RuleSAO’BrienSGCrossmanLC. Managing cutaneous reactions to imatinib therapy. Blood2002; 100: 3434–3435.
8.
Quintas-CardamaACortesJEKantarjianH. Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma2008; 8(Suppl 3): S82–S88.
9.
DeRemerDLUstunCNatarajanK. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther2008; 30: 1956–1975.
10.
HuangXPatelSAhmedN. Severe toxicity of skin rash, fever and diarrhea associated with imatinib: case report and review of skin toxicities associated with tyrosine kinase inhibitors. Drug Des Devel Ther2009; 2: 215–219.
